206 related articles for article (PubMed ID: 38037138)
1. A systematic literature review on direct and indirect costs of triple-negative breast cancer.
Rezaei S; Babaei M
Cost Eff Resour Alloc; 2023 Nov; 21(1):92. PubMed ID: 38037138
[TBL] [Abstract][Full Text] [Related]
2. Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review.
Huang M; Haiderali A; Fox GE; Frederickson A; Cortes J; Fasching PA; O'Shaughnessy J
Pharmacoeconomics; 2022 May; 40(5):519-558. PubMed ID: 35112331
[TBL] [Abstract][Full Text] [Related]
3. Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer.
Hsu JY; Chang CJ; Cheng JS
Sci Rep; 2022 Jan; 12(1):729. PubMed ID: 35031634
[TBL] [Abstract][Full Text] [Related]
4. Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review.
Franklin M; Pollard D; Sah J; Rayner A; Sun Y; Dube F; Sutton A; Qin L
Adv Ther; 2024 Jul; 41(7):2700-2722. PubMed ID: 38833143
[TBL] [Abstract][Full Text] [Related]
5. Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach.
Kim H; Kim HJ; Kim H; Kim HR; Jo H; Hong J; Kim R; Kim JY; Ahn JS; Im YH; Lee SK; Kim H; Shin SY; Park YH
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830990
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Assessing direct costs of treating metastatic triple-negative breast cancer in the USA.
Skinner KE; Haiderali A; Huang M; Schwartzberg LS
J Comp Eff Res; 2021 Feb; 10(2):109-118. PubMed ID: 33167695
[No Abstract] [Full Text] [Related]
8. The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States.
Sieluk J; Song Y; Freimark J; Huang M; Haiderali A; Berman R; Wang T; Signorovitch J; Hirshfield KM
Adv Ther; 2022 Feb; 39(2):943-958. PubMed ID: 34918193
[TBL] [Abstract][Full Text] [Related]
9. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
Li CH; Karantza V; Aktan G; Lala M
Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
[TBL] [Abstract][Full Text] [Related]
10. The direct and indirect costs associated with endometriosis: a systematic literature review.
Soliman AM; Yang H; Du EX; Kelley C; Winkel C
Hum Reprod; 2016 Apr; 31(4):712-22. PubMed ID: 26851604
[TBL] [Abstract][Full Text] [Related]
11. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021.
Jaber Chehayeb R; Hood A; Wang X; Miksad R; Schellhorn Mougalian S; Lustberg MB; Wang SY; Greenup RA; Pusztai L; Kunst N
JAMA Netw Open; 2022 Nov; 5(11):e2244204. PubMed ID: 36445704
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
13. Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer.
Celik A; Berg T; Jensen MB; Jakobsen E; Nielsen HM; Kümler I; Glavicic V; Jensen JD; Knoop A
Breast Cancer (Auckl); 2023; 17():11782234231203292. PubMed ID: 37810797
[TBL] [Abstract][Full Text] [Related]
14. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry.
Baser O; Wei W; Henk HJ; Teitelbaum A; Xie L
Curr Med Res Opin; 2012 Mar; 28(3):419-28. PubMed ID: 22364568
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and healthcare resource utilization for triple negative breast cancer in the Brazilian private healthcare system: a database study.
Carlos Souto Maior Borba MA; de Mendonça Batista P; Falcão Almeida M; do Carmo Rego MA; Brandão Serra F; Barbour Oliveira JC; Nakajima K; Silva Julian G; Amorim G
Sci Rep; 2023 Sep; 13(1):15785. PubMed ID: 37737435
[TBL] [Abstract][Full Text] [Related]
16. Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.
Landry I; Sumbly V; Vest M
Cureus; 2022 Feb; 14(2):e21970. PubMed ID: 35282535
[TBL] [Abstract][Full Text] [Related]
17. Platinum-containing regimens for metastatic breast cancer.
Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of smoking: a systematic review of direct and indirect costs.
Rezaei S; Akbari Sari A; Arab M; Majdzadeh R; Mohammad Poorasl A
Med J Islam Repub Iran; 2016; 30():397. PubMed ID: 27579287
[TBL] [Abstract][Full Text] [Related]
19. Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries.
Kotzeva A; Mittal D; Desai S; Judge D; Samanta K
J Med Econ; 2023; 26(1):70-83. PubMed ID: 36503357
[TBL] [Abstract][Full Text] [Related]
20. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
Ekpu VU; Brown AK
Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
